A Clinical Trial With SENS-601, Injected With SPHYNX Administration System, in the Pediatric Population Presenting With Hearing Loss Related to Pathogenic Variation(s) of GJB2 Gene (HEARCONNEX)
An Open-Label, Multicenter Phase 1/2 Study to Assess the Safety, Tolerability, and Efficacy of Intracochlear Ascending Dose Injections of SENS-601 Followed by Expansion Cohort in Pediatric Population With Hearing Loss Related to Biallelic Pathogenic Variation(s) of GJB2, As Well As to Demonstrate the Performance of the Administration System, Its Safety, Its Clinical Benefit, and Its Usability
This study intends to assess safety, tolerability, and efficacy of SENS-601, injected with SPHYNX administration system, in children between 6 months and 6 years of age, with hearing loss related to pathogenic variation(s) of GJB2 gene.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Lionel HOVSEPIAN
- Telefonnummer: +33(0)686 831 180
- E-mail: contact@sensorion-pharma.com
Studiesteder
-
-
-
Paris, Frankrig, 75015
- Rekruttering
- Hopital Necker Enfants Malades
-
Kontakt:
- Centre de Recherche en Audiologie pédiatrique
- Telefonnummer: +33(0)187 892 916
- E-mail: rdv.crea.nck@aphp.fr
-
Ledende efterforsker:
- Natalie LOUNDON
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Males or females aged ≥6 months to ≤6 years.
- Congenital bilateral severe sensorineural hearing loss.
- Biallelic GJB2 variation(s).
- Documented normal cochlea and internal auditory canals.
Exclusion Criteria:
- History of chronic, acute, or major disease.
- Have been dosed in a previous gene therapy clinical study.
- Other causes or risk of hearing loss, including developmental disorders, unilateral hearing loss, chronic conductive hearing loss, malformation syndrome, syndromic hearing loss or any other cause that would impact negatively the response of hair cell function, history of therapy known as ototoxic for an extended period, or documented other causes of congenital bilateral hearing loss linked to mutations in genes other than GJB2.
- Prior or current cochlear implant in the ear to be treated with SENS-601.
- Contraindication to corticosteroid therapy and/or immunosuppressive or immunomodulatory therapy or to the planned surgery, to anesthesia or increased anesthesiologic risk.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Dose escalation - Dose Level 1
Intracochlear administration of Dose level 1 of SENS-601 in one ear, with the SPHYNX injection system |
Administration of SENS-601 with the SPHYNX injection system |
|
Eksperimentel: Dose escalation - Dose Level 2
Intracochlear administration of Dose level 2 of SENS-601 in one ear, with the SPHYNX injection system |
Administration of SENS-601 with the SPHYNX injection system |
|
Eksperimentel: Dose expansion group
Intracochlear administration of SENS-601 in both ears, with the SPHYNX injection system, at the dose recommended following the Dose escalation phase |
Administration of SENS-601 with the SPHYNX injection system |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety and tolerability of SENS-601 and SPHYNX administration system
Tidsramme: 5 years
|
The incidence and severity of Treatment-Emergent Adverse Events (TEAEs). The incidence and severity of Adverse Device Events, Serious Adverse Device Effects, and Device Deficiencies |
5 years
|
|
Efficacy of SENS-601 assessed by ABR
Tidsramme: 5 years
|
Change from baseline of hearing threshold measured by auditory brainstem response (ABR) |
5 years
|
|
Efficacy of SENS-601 assessed by PTA
Tidsramme: 5 years
|
Change from baseline of hearing threshold measured by pure-tone audiometry (PTA) |
5 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
SPHYNX Injection system performance
Tidsramme: Day 1
|
Incidence of successful administrations, based on user questionnaires |
Day 1
|
|
SPHYNX Injection System clinical benefit
Tidsramme: Day 1
|
Incidence of failed surgeries due to SPHYNX injection system, based on "SENS-601 injection form" user questionnaires |
Day 1
|
|
Usability of the administration system
Tidsramme: Day 1
|
Evaluation of the degree to which users were able to effectively, efficiently, and safely use the devices in their specific environments, based on "Usability assessment" user questionnaire |
Day 1
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- SENS-601-101
- 2026-525698-38-00 (Ctis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .